Cerebrolysin Research Guide: Porcine Neuropeptide Complex & Half-Life
Cerebrolysin is a peptide-and-amino-acid complex derived from purified porcine brain tissue, studied for neurotrophic effects in stroke and cognitive research.
What is Cerebrolysin?
Cerebrolysin is a complex parenteral preparation containing free amino acids and low-molecular-weight peptides (most under 10 kDa) derived from enzymatically digested, purified porcine brain tissue. It is manufactured by EVER Pharma in Austria.
Unlike single-molecule research peptides, Cerebrolysin is a defined peptide-and-amino-acid complex, and it is approved in approximately 50 countries (primarily in Europe, Asia, and Latin America) for indications including ischemic stroke, traumatic brain injury, and dementia.
Mechanism of action
The peptide fraction of Cerebrolysin is thought to mimic the action of endogenous neurotrophic factors — particularly BDNF, NGF, GDNF, and CNTF — at multiple levels of the neurotrophic signaling cascade.
Animal studies report enhanced neuronal survival under ischemic stress, upregulation of synaptic plasticity markers, and modest neurogenesis in the dentate gyrus and subventricular zone.
Clinical data
Cochrane and other meta-analyses of randomized trials show modest but consistent functional-outcome improvements in acute ischemic stroke when Cerebrolysin is added to standard care. Studies in traumatic brain injury (e.g., CAPTAIN trials) and vascular cognitive impairment have shown similar signals.
Compliance reminder
Cerebrolysin is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is Cerebrolysin?
Cerebrolysin is a parenteral preparation containing a mixture of low-molecular-weight peptides (~85%) and free amino acids (~15%) derived from purified porcine brain tissue. It is approved in roughly 50 countries for neurological indications.
Mechanism?
The peptide fraction is thought to mimic the action of endogenous neurotrophic factors — particularly BDNF, NGF, GDNF, and CNTF — supporting neuronal survival, synaptic plasticity, and neurogenesis in animal stroke and TBI models.
What does the research show?
Meta-analyses of clinical trials show modest but consistent improvements in functional outcome after ischemic stroke and traumatic brain injury, and some signal in vascular cognitive impairment studies.